Flemming Julia, Marczenke Maike, Rudolph Ina-Maria, Nielsen Rikke, Storm Tina, Erik Ilsoe Christensen, Diecke Sebastian, Emma Francesco, Willnow Thomas E
Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Department of Biomedicine, Faculty of Health Science, Aarhus University, Aarhus C, Denmark.
Kidney Int. 2020 Jul;98(1):159-167. doi: 10.1016/j.kint.2020.02.021. Epub 2020 Mar 24.
Donnai-Barrow syndrome (DBS) is an autosomal-recessive disorder characterized by multiple pathologies including malformation of forebrain and eyes, as well as resorption defects of the kidney proximal tubule. The underlying cause of DBS are mutations in LRP2, encoding the multifunctional endocytic receptor megalin. Here, we identified a unique missense mutation R3192Q of LRP2 in an affected family that may provide novel insights into the molecular causes of receptor dysfunction in the kidney proximal tubule and other tissues affected in DBS. Using patient-derived induced pluripotent stem cell lines we generated neuroepithelial and kidney cell types as models of the disease. Using these cell models, we documented the inability of megalin R3192Q to properly discharge ligand and ligand-induced receptor decay in lysosomes. Thus, mutant receptors are aberrantly targeted to lysosomes for catabolism, essentially depleting megalin in the presence of ligand in this affected family.
多纳伊 - 巴罗综合征(DBS)是一种常染色体隐性疾病,其特征为多种病变,包括前脑和眼睛畸形以及肾近端小管的重吸收缺陷。DBS的根本原因是LRP2基因突变,该基因编码多功能内吞受体巨蛋白。在此,我们在一个患病家族中鉴定出LRP2的一个独特错义突变R3192Q,这可能为深入了解肾近端小管及DBS中其他受影响组织中受体功能障碍的分子原因提供新线索。我们使用患者来源的诱导多能干细胞系生成神经上皮和肾细胞类型作为该疾病的模型。利用这些细胞模型,我们证明了巨蛋白R3192Q无法在溶酶体中正常释放配体以及配体诱导的受体降解。因此,突变受体异常靶向溶酶体进行分解代谢,在这个患病家族中,在存在配体的情况下基本上耗尽了巨蛋白。